Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2026 07:00 ET | Source: iBio, Inc.

iBio Announces $26 Million Private Placement

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase...
November 24, 2025 16:15 ET | Source: iBio, Inc.

iBio to Participate in the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore...
November 12, 2025 16:01 ET | Source: iBio, Inc.

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds ...
October 30, 2025 07:00 ET | Source: iBio, Inc.

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment...
October 23, 2025 07:00 ET | Source: iBio, Inc.

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual...
October 21, 2025 07:00 ET | Source: iBio, Inc.

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and...